Form 4: Aileron Therapeutics Director Josef H. von Rickenbach Reports Stock Option Grant

Director Josef H. von Rickenbach reports the grant of a stock option for Aileron Therapeutics shares.

Summary

• Josef H. von Rickenbach, a director of Aileron Therapeutics, Inc., filed a Form 4 on August 22, 2024, reporting a transaction.
• On August 20, 2024, von Rickenbach was granted a stock option to purchase 2,725 shares of Aileron Therapeutics common stock at an exercise price of $2.40.
• The option vests in full on the earlier of August 20, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders.
• Brian Windsor is acting as attorney-in-fact for Josef H. von Rickenbach, authorized to file Section 16 reports on his behalf.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation, with a neutral sentiment.

Positives

• The grant of stock options to directors can align their interests with those of shareholders, incentivizing them to work towards increasing the company's value.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting ownership if the options are exercised.

Key Dates